Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients

Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients

Background: The biomarkers of immune checkpoint inhibitors (ICIs) efficacy and safety are still urgently needed. As cytokines are easily detected and monitored in circulation, they could be used as potential predictors of response and immune-related adverse events (irAEs) for ICIs therapy. Methods:...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Katarina Mirjačić Martinović, Ana Vuletić, Nevena Tišma Miletić, Irina Besu Žižak, Jelena Milovanović, Suzana Matković, Vladimir Jurišić
Μορφή:	Άρθρο
Γλώσσα:	English
Έκδοση:	Elsevier 2023-12-01
Σειρά:	Translational Oncology
Θέματα:	Metastatic melanoma patients BRAF wild type Pembrolizumab Cytokines Monitoring Outcome predictors
Διαθέσιμο Online:	http://www.sciencedirect.com/science/article/pii/S1936523323001857

Παρόμοια τεκμήρια

Complete response in a patient with BRAF-mutant metastatic melanoma achieved with the multidisciplinary approach: a case report
ανά: Hana Garaj, κ.ά.
Έκδοση: (2024-01-01)

Factors influencing the prognosis in Braf wild-type metastatic malignant melanoma and the role of novel inflammation indices
ανά: Senar Ebinç, κ.ά.
Έκδοση: (2023-09-01)

A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
ανά: Wu L, κ.ά.
Έκδοση: (2021-02-01)

Increased circulating monocyte MDSCs positively correlate with serum Interleukin-10 in metastatic melanoma patients
ανά: Katarina Mirjačić Martinović, κ.ά.
Έκδοση: (2023-04-01)

Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives
ανά: Dugan MM, κ.ά.
Έκδοση: (2024-07-01)

Clinical significance of <it>BRAF </it>mutations in metastatic melanoma
ανά: Polsky David, κ.ά.
Έκδοση: (2004-12-01)

A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report
ανά: Francesca Consoli, κ.ά.
Έκδοση: (2020-07-01)

Case report: Exceptional disease progression in a 70-year-old patient: generalized melanosis and melanuria in the course of metastatic melanoma - a case study
ανά: Jacek Calik, κ.ά.
Έκδοση: (2024-01-01)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
ανά: Justin C. Moser, κ.ά.
Έκδοση: (2019-12-01)

Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease
ανά: Xiang Dan, κ.ά.
Έκδοση: (2024-04-01)

PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA
ανά: I. V. SAMOILENKO, κ.ά.
Έκδοση: (2017-06-01)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive <i>BRAF</i> Mutant Advanced Melanoma
ανά: Ernesto Rossi, κ.ά.
Έκδοση: (2023-01-01)

A phase I, single‐center, open‐label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [14C] encorafenib in healthy male subjects
ανά: Lance Wollenberg, κ.ά.
Έκδοση: (2023-10-01)

Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report
ανά: Bartoušková Marie, κ.ά.
Έκδοση: (2020-08-01)

Systemic therapy of skin metastatic melanoma with BRAF gene mutation
ανά: Yu. S. Shakh-Paronyants, κ.ά.
Έκδοση: (2023-03-01)

A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
ανά: Dahlia Fedele, κ.ά.
Έκδοση: (2024-01-01)

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
ανά: Saba S. Shaikh, κ.ά.
Έκδοση: (2022-11-01)

Detection of humoral and cellular immune response to anti-SARS-CoV-2 BNT162b2 vaccine in breastfeeding women and naïve and previously infected individuals
ανά: Milena Cavic, κ.ά.
Έκδοση: (2023-04-01)

Melanoma: BRAFi Rechallenge
ανά: Christoforos S. Kosmidis, κ.ά.
Έκδοση: (2023-05-01)

Limbic encephalitis in metastatic malignant melanoma patient induced by PD-1 checkpoint inhibitor pembrolizumab
ανά: Rozala Arko, κ.ά.
Έκδοση: (2022-07-01)

MEK inhibitors for the treatment of NRAS mutant melanoma
ανά: Sarkisian S, κ.ά.
Έκδοση: (2018-08-01)

The Human Melanoma Proteome Atlas—Complementing the melanoma transcriptome
ανά: Lazaro Hiram Betancourt, κ.ά.
Έκδοση: (2021-07-01)

Current State of Target Treatment in BRAF Mutated Melanoma
ανά: Enrica Teresa Tanda, κ.ά.
Έκδοση: (2020-07-01)

Fertility Outcomes and Sperm-DNA Parameters in Metastatic Melanoma Survivors Receiving Vemurafenib or Dabrafenib Therapy: Case Report
ανά: Marco Ghezzi, κ.ά.
Έκδοση: (2020-03-01)

Novel 5,6-dichlorobenzimidazole derivatives as dual BRAFWT and BRAFV600E inhibitors: design, synthesis, anti-cancer activity and molecular dynamics simulations
ανά: Ahmed Temirak, κ.ά.
Έκδοση: (2025-02-01)

Update on the treatment of BRAFmut metastatic melanoma and future perspectives
ανά: Peter Mohr, κ.ά.
Έκδοση: (2025-03-01)

BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma
ανά: Karam Khaddour, κ.ά.
Έκδοση: (2021-06-01)

Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study
ανά: Igor V. Samoylenko, κ.ά.
Έκδοση: (2024-10-01)

Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma
ανά: Adi Kartolo, κ.ά.
Έκδοση: (2022-03-01)

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review
ανά: Simeng Zhang, κ.ά.
Έκδοση: (2023-01-01)

Rapidly progressing metastatic malignant melanoma mimicking primary pleural tumor: A case report
ανά: Clara So, κ.ά.
Έκδοση: (2022-05-01)

Braf protein mutation and its significancy within patients with melanoma
ανά: Julia Kuchnicka, κ.ά.
Έκδοση: (2022-08-01)

Treatment of Advanced Melanoma: Past, Present and Future
ανά: Taku Fujimura, κ.ά.
Έκδοση: (2020-09-01)

Comparison of Two Rapid Assays for the Detection of <i>BRAF</i> V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes
ανά: Elodie Long-Mira, κ.ά.
Έκδοση: (2022-03-01)

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
ανά: Walid Shalata, κ.ά.
Έκδοση: (2023-02-01)

Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
ανά: Nakul Dar, κ.ά.
Έκδοση: (2023-08-01)

Tyrosine kinase inhibitors via nasogastric tube may resolve severe ileus secondary to melanoma: A case report
ανά: Lena Groennendijk, κ.ά.
Έκδοση: (2022-06-01)

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma
ανά: Francesco Serra, κ.ά.
Έκδοση: (2021-08-01)

Association between braf gene mutation status and clinical-morphological features of cutaneous melanoma
ανά: O. I. Kit, κ.ά.
Έκδοση: (2016-06-01)

Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome
ανά: Sim Vermeulen, κ.ά.
Έκδοση: (2021-04-01)